• BLU-667: New Hope for NSCLC and Medullary Thyroid Cancer

    7 monthes ago - By Medscape

    RET mutations and rearrangements have been identified across several solid tumors, including non-small cell lung cancer , and for the first time, a new potent inhibitor shows activity in humans.
    Medscape Medical News
    Read more ...

     

  • New Drug Therapy Shows Promise to Treat Multiple Cancers

    7 monthes ago - By Medindia Health

    A novel drug has been developed for treating cancers caused by receptor tyrosine kinase. BLU-667 drug is the novel, investigational drug, which was chosen as it is 100 times more selective for RET-driven cancers.
    Read more ...